No Picture
News

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, tod… […]

No Picture
News

Global Genes Report Finds Technology Reshaping the Rare Disease Landscape, but Non-Scientific Challenges Threaten to Impede Progress

Report seeks to foster creative thinking and new approaches to addressing obstacles to patients getting the answers and care they need

ALISO VIEJO, Calif., Sept. 18, 2019 /PRNewswire/ — The rapid progress of technology is creating an opportunity to … […]

No Picture
News

INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

La Jolla, CA., Sept. 17, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder… […]

No Picture
News

AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting

SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that it has signed a cultivation agreement wit… […]